ipod on pc
ipod on pc with http://www.mdnewscast.net

ipod on pc

Medical Newscast

News for 31-Jan-26

Source: MedicineNet High Blood Pressure General
Yoga Called Good Medicine for High Blood Pressure

Source: MedicineNet Diabetes General
FDA OKs High-Tech Diabetes Device to Help Replace Fingerstick Tests

Source: MedicineNet High Blood Pressure General
Bonus From Your Blood Pressure Med: Fewer Fractures?

Source: MedicineNet Diabetes General
Daily Can of Soda Boosts Odds for Prediabetes, Study Finds

Source: MedicineNet High Blood Pressure General
Normal Blood Pressure in Clinic May Mask Hypertension

Source: MedicineNet Diabetes General
Health Tip: Prepare for Travel With Diabetes

Source: MedicineNet High Blood Pressure General
Omega-3s a Recipe for Healthy Blood Pressure in Young Adults

Source: MedicineNet High Blood Pressure General
Sharp Drop in Blood Pressure After Rx May Be Risky for Some Heart Patients

Source: MedicineNet Diabetes General
Health Tip: Creating an Insulin Routine

Source: MedicineNet Diabetes General
Chemo More Damaging to Hearts of Diabetics: Study

Search the Web
ipod on pc
ipod skin
ipod windows 98
ipod transfer
isee ipod
apple ipod 10gb
ipod sync
new apple ipod
ipod 40gb
apple ipod 20gb

The Best ipod on pc website

All the ipod on pc information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best ipod on pc site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
ipod on pc.

ipod on pc

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

Knowing you're getting value for money is very important in buying ipod on pc, so by coming to this web site you can rest with the sound knowledge that you are getting the ipod on pc you paid for.

By buying through our recommend links you can also rest assured your ipod on pc will be of the highest quality. How do we know? Because when we're shopping for ipod on pc ourselves it's where we go.

You might wonder why we're suggesting you click on some outside links rather than stay on our ipod on pc site. Well it's because we've only just put this site up and haven't yet got it fully operational. Our aim is to be the best site for ipod on pc info on the net, and I'm sure that one day soon we'll achieve it. So please bookmark us and come back soon. Meanwhile please follow one of the links.

ipod on pc

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

The time for standing in place is gone and anyone who wants the best in ipod on pc should understand that. There are many people who want to know more about ipod on pc and since you are here you must be one of them. Anyway we are happy to have you as a visitor and want to make your visit worthwhile.

There are a number of ipod on pc websites on the Internet as you surely know. Some are worthwhile and others are completely worthless. We pride ourselves on providing only the most valuable information on ipod on pc available.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
Medical Meetings On The Net | Medical Meetings | Fantasy Baseball Online | Medical Newscast | Doctors On-the-Net

Take It Correctly   Medical Newscast   MD Newscast